

## **2<sup>nd</sup> International Workshop on Standards and Measurements for Alpha-Emitting Radionuclides in Therapeutic Nuclear Medicine**

**Organized by:** the Consultative Committee on Ionizing Radiation (CCRI) of the Bureau International des Poids et Mesures (BIPM), in collaboration with the EURAMET AlphaMet project

**Venue:** Bureau International des Poids et Mesures Headquarters, Sèvres, France

**Dates:** 5-7 May 2026

This two-and-a-half-day workshop builds on the successful first workshop, held in February 2024 (<https://www.bipm.org/en/committees/cc/ccri/wg/ccri-rtwg/2024-02-22>). It is intended to bring together once again practitioners from the radionuclide metrology, nuclear medicine, and medical physics communities to discuss issues and needs for accurate measurements and standards for alpha-emitting radionuclides being used or investigated for therapeutic nuclear medicine applications. Participation from the radiopharmacies, isotope producers, regulators, and radiopharmaceutical manufacturers will also be a critical part of the workshop.

The workshop is expected to provide an update on progress made during the past two years in the development and dissemination of measurement standards for Targeted Alpha Therapy (TAT) and in clinical applications, particularly clinical and preclinical dosimetry. There will be a particular focus on traceability, clinical implementation, engagement with regulators and professional societies, and future directions.

As with the previous workshop, a document summarizing the main points and outcomes of the workshop will be prepared and made publicly available. The summary of the previous workshop can be found here: <https://doi.org/10.1016/j.apradiso.2025.111827>.

Specific topics to be addressed are:

- Status of current clinical trials, new applications/indications for TAT
- Dosimetry-based treatment planning and optimization for TAT
- A roundtable discussion with manufacturers on topics such as traceability, product supply, dosimetry in trials, and equivalence and standards in global markets
- Current efforts in the establishment of secondary standards laboratories (e.g., PDIB, ETRAIN)
- Preclinical imaging/dosimetry

- Traceability and the international metrology infrastructure for radioactivity measurement in nuclear medicine
- Radioactivity standards for alpha-emitting radionuclides
- Nuclear and atomic decay data updates

The draft Agenda is expected in early November, 2025 and will be posted to the Working Group web site (<https://www.bipm.org/en/committees/cc/ccri/wg/ccri-rtwg>).